THE FGF19-CHOLESTYRAMINE (F-CME) TEST AS A TWO-STAGE METHOD FOR ROUTINE CANCER SCREENING
Number of patents in Portfolio can not be more than 2000
United States of America
Stats
-
N/A
Issued Date -
Mar 17, 2022
app pub date -
Aug 24, 2021
filing date -
Aug 24, 2021
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
Disclosed is a two-staged, generalized cancer screening concept modeled closely after a suppression test. The test is blood based, and screens for elevated levels of Fibroblast Growth Factor 19 (FGF19), a cancer biomarker expressed across a majority of cancers, via standard enzyme-linked immunosorbent assay (ELISA). Unlike other biomarker-based blood tests that rely on a single-blood draw, the F-CME test validates cancer with a follow-up test using oral cholestyramine as the “suppression” drug.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully